Aminoglutethimide and warfarin. A new important drug interaction.
Aminoglutethimide (AG) has recently been introduced for endocrine therapy in patients with advanced breast and endometrial cancer. In this study two patients being treated with both AG and the anticoagulant agent warfarin are described. An important drug interaction was observed, resulting in a decrease in the anticoagulant effect of warfarin. This was shown by means of thrombotest measurements and pharmacokinetic evaluation of warfarin. A 3- to 5-fold increase in warfarin clearance was found. This interaction is probably due to an AG-promoted induction of hepatic microsomal enzymes accelerating warfarin metabolism.